Federal Circuit Finds Method-of-Treatment Claims Including In Vivo Dosing Limitations Are Not Enabled By In Vitro Data
In Wyeth LLC v. AstraZeneca Pharmaceuticals LP , the Federal Circuit affirmed judgment as a matter of law that Wyeth's method-of-treatment claims were invalid for lack of enablement, wiping out a…
Read the full articleYou might also wanna read
STAT+: Pharmalittle: We’re reading about a battle between Lilly and Teva, psychedelic drugs, and more
A U.S. appeals court revived a Teva Pharmaceuticals lawsuit accusing Eli Lilly of breaching an agreement allowing Teva to market a generic
Compounded peptides placed on restrictive list by FDA, lawsuit filed
The FDA is evaluating the future of compounded peptides, which are popular short-chain amino acids that signal cells to perform specific bio
Pfizer Aktie: FDA lässt PADCEV-Kombi zu
Die US-Gesundheitsbehörde FDA hat die Kombination aus PADCEV und Keytruda für die Behandlung von Patienten mit muskelinvasivem Blasenkrebs (
Outlook Therapeutics Aktie: FDA entscheidet am 29. Juli
Neunzehn Tage bleiben Outlook Therapeutics bis zur wichtigsten Entscheidung ihrer Firmengeschichte. Bis zum 29. Juli muss die US-Arzneimitte
Federal jury rules against Prevagen maker in deceptive marketing case over unsubstantiated memory claims
Verdict comes nine years after TINA.org alerted regulator to supplement's unsubstantiated health claims.
truthinadvertising.org·23d agoScience, Tylenol and Autism
When claims are made that one of the most widely used medications during pregnancy may cause autism, the public understandably pays attentio
Comments
Sign in to join the conversation.
No comments yet. Be the first.